Special Interest

Intraoperative Care of the Cancer Patient: Can Anesthetic Technique Promote Metastasis in the Postoperative Period? (1 Class A CE with .5 Pharm)

Saturday, September 22
11:45 AM - 12:45 PM
Location: Ballroom C, Hynes

A knowledge of physiologic defense mechanisms against malignant cells, the inherent stressors present during the perioperative period which may promote metastasis, and the potential deleterious effect of certain commonly utilized anesthetics on natural killer cell activity may guide the anesthetist to formulate a more pointed plan when caring for the cancer patient undergoing surgery.

Learning Objectives:

Marianne S. Cosgrove, DNAP, CRNA, APRN

Program Director
Yale New Haven Hospital School of Nurse Anesthesia
Madison, Connecticut

Marianne Cosgrove is a 1990 graduate of the Yale New Haven Hospital School of Nurse Anesthesia. She received her Master’s degree in the Biological Sciences: Anesthesia from Central CT State University in 1993 and a Doctor of Nurse Anesthesia Practice degree from Virginia Commonwealth University in 2011. She is presently a Clinical Faculty member at Yale University, the program director of the Yale New Haven Hospital School of Nurse Anesthesia and a practicing CRNA at YNHH. She is the co-owner of Core Concepts Anesthesia Review, LLC. Dr. Cosgrove is currently a Ph.D. candidate at VCU. Her dissertation research is focused on the effect of elevated ambient noise in the OR on anesthetist situation awareness and performance, particularly during critical phases of the anesthetic.

Presentation(s):

Send Email for Marianne Cosgrove


Assets

Intraoperative Care of the Cancer Patient: Can Anesthetic Technique Promote Metastasis in the Postoperative Period? (1 Class A CE with .5 Pharm)

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Intraoperative Care of the Cancer Patient: Can Anesthetic Technique Promote Metastasis in the Postoperative Period? (1 Class A CE with .5 Pharm)